Inhalers and nebulizers okay during COVID-19 infections

Sign up for Scientific Inquirer’s Steady State Newsletter for the week’s top stories, exclusive interviews, and weekly giveaways. Plenty of value added but without the tax.

The benefits of using inhalers and nebulisers containing steroids outweigh the risks despite warnings to the contrary during the COVID-19 pandemic, a study by University of Huddersfield researchers has found.

A warning issued by WHO in March advised that steroids used in inhalers and nebulisers could have a negative effect on a user’s immunity system, leaving them more susceptible to COVID-19. The concern was that regular steroid use could leave users vulnerable to contracting the virus, or developing a more severe version than non-users.

WHO’s cautionary note caused worry for people with asthma or chronic obstructive pulmonary disease (COPD), leaving them unsure about whether they could keep using inhalers and nebulisers or not. The British Thoracic Society had reported that demand for inhalers had jumped by 400%, leading to shortages in the UK, following WHO’s announcement.

However, Dr Hamid Merchant and Dr Syed Shahzad Hasan from the University of Huddersfield commissioned research into the use of steroids and risk of infections, especially viral infections of the upper respiratory tract. That included previous outbreaks of SARS, as well as the COVID-19 pandemic.

“It confused a lot of people,” says Dr Hasan. “After the WHO advice, people thought that continuous use of steroids would leave them at a greater risk of contracting the virus or developing more than a mild version of CoViD-19.”

Inhaled corticosteroids (ICS) and oral corticosteroids (OCS) are prescribed to help asthma sufferers and those with COPD, with inhalers used to prevent attacks.

The study has been published in Respiratory Medicine, having assessed evidence and findings from a range of bodies including the British Thoracic Society and the National Institute for Health and Care Excellence (NICE). The other authors in the study included Toby Capstick (a consultant pharmacist on respiratory medicine at Leeds Teaching Hospitals NHS Trust), Syed Tabish Zaidi (Associate Professor in Pharmacy at the University of Leeds) and Chia Siang Kow (a clinical pharmacist from Malaysia).

“We found there is strong evidence that the benefits of continuing with steroids outweighs the risk,” declares Dr Merchant.

“There is a risk that the immune system goes down, and there is a chance of acquiring infections but the benefits of continuing with steroids throughout were higher than the risks. We concluded by saying that the patients should continue their regular medicines including steroids.”

IMAGE SOURCE: Creative Commons

Words matter. Images matter. The Scientific Inquirer needs your support. Help us pay our contributors for their hard work. Visit our Patreon page and discover ways that you can make a difference.

Leave a Reply

%d bloggers like this: